HCW Biologics Q2 FY26 net loss widens to $5.2 million; revenue rises to $135,568

Reuters2026/08/14 19:15

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

HCW Biologics posted Q2 net loss of USD 5.2 million, widening from USD 1.9 million a year earlier.
Revenue climbed to USD 135,568 from USD 6,550; R&D held at USD 1.2 million while G&A fell 11% to USD 1.9 million.
Six-month revenue rose to USD 6.7 million from USD 11,615, driven by closing the Trimmune License for HCW11-006 in vivo rights.
HCW9302 Phase 1 alopecia areata study showed early SALT score improvements in cohort two; no dose-limiting toxicities reported.
Management said HCW9302’s CD25 targeting supports regulatory T-cell expansion; full Phase 1 readout remains slated for Q4 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HCW Biologics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608141515PRIMZONEFULLFEED9810579) on August 14, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

HCW Biologics Q2 FY26 net loss widens to $5.2 million; revenue rises to $135,568

You may also like

Crypto prices